Tango Therapeutics, Inc.
NASDAQ•TNGX
CEO: Dr. Barbara L. Weber M.D.
Sector: Healthcare
Industry: Biotechnology
Listing Date: 2020-09-03
Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company develops TNG462, an oral small molecule methylthioadenosine-cooperative inhibitor for the treatment for cancers with methylthioadenosine phosphorylase deletions; TNG260, a co-repressor of repressor element-1 silencing transcription -selective inhibitor; TNG348, an ubiquitin-specific protease 1 inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. It has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. Tango Therapeutics, Inc. was founded in 2017 and is headquartered in Boston, Massachusetts.
Contact Information
Market Cap
$1.44B
P/E (TTM)
-14.4
38.2
Dividend Yield
--
52W High
$13.18
52W Low
$1.03
52W Range
Rank51Top 71.3%
3.0
F-Score
Modified Piotroski Analysis
Based on 6-year fundamentals
Weak • 3 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2020-2025
Financial Dashboard
Q3 2025 Data
Revenue
$53.81M+363.61%
4-Quarter Trend
EPS
$0.14-153.00%
4-Quarter Trend
FCF
-$31.10M-7.17%
4-Quarter Trend
2025 Q3 Earnings Highlights
Key Highlights
Q3 Revenue Driven by Recognition Collaboration revenue reached $53.8M USD in Q3 2025, up $42.2M from $11.6M Q3 2024 due to Gilead agreement truncation.
Return to Quarterly Profitability Q3 Net Income was $15.9M USD, a significant swing from Q3 2024 Net Loss of $(29.2)M USD; 9M Loss narrowed.
Vopimetostat Positive Data Vopimetostat Phase 1/2 showed 27% ORR across 94 patients; planning pivotal trial initiation for 2L pancreatic cancer in 2026.
Liquidity Runway Extended October 2025 financing provided $212.0M net proceeds, enabling funding of operating expenses and capital needs into 2028.
Risk Factors
Continued Operating Losses Expected Expect continued significant operating losses and negative cash flow for foreseeable future; substantial additional funding required.
Key Program Discontinuations TNG348 discontinued due to toxicity; TNG908 enrollment halted due to insufficient GBM activity, impacting R&D focus.
Regulatory Review Uncertainty New administration policies create uncertainty regarding FDA review timelines, guidance, and potential challenges to approval pathways.
Outlook
Pivotal Trial Planning Underway Planning initiation of pivotal trial for vopimetostat in second line MTAP-deleted pancreatic cancer, anticipated to start in 2026.
Advancing Next Generation Candidates Advancing TNG456 for CNS cancers and TNG961 targeting HBS1L in FOCAD-deleted solid tumors development programs.
Expert Consulting Engaged Engaged expert consultants to support planned pivotal study initiation and advance late-stage clinical development capabilities.
Peer Comparison
Revenue (TTM)
ANAB$169.47M
$167.36M
$104.03M
Gross Margin (Latest Quarter)
100.0%
100.0%
99.0%
Key Metrics
Symbol | Market Cap | P/E (TTM) | ROE (TTM) | Debt to Assets |
|---|---|---|---|---|
| TNGX | $1.44B | -14.4 | -60.8% | 16.5% |
| PGEN | $1.32B | -5.3 | -3342.6% | 57.3% |
| RLAY | $1.27B | -4.3 | -42.9% | 5.0% |
Long-Term Trends
Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
135.6%
Strong Growth
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
0%
Cash Flow Needs Attention
Research & Insights
Next earnings:Feb 26, 2026
EPS:-$0.31
|Revenue:-
Reports
All Years
Form 10-Q - Q3 2025
Period End: Sep 30, 2025|Filed: Nov 4, 2025|Revenue: $53.81M+363.6%|EPS: $0.14-153.0%BeatForm 10-Q - Q2 2025
Period End: Jun 30, 2025|Filed: Aug 5, 2025|Revenue: $3.18M-84.0%|EPS: $-0.35+45.8%MeetForm 10-Q - Q1 2025
Period End: Mar 31, 2025|Filed: May 12, 2025|Revenue: $5.39M-16.7%|EPS: $-0.36+2.9%MeetForm 10-K - FY 2024
Period End: Dec 31, 2024|Filed: Feb 27, 2025|Revenue: $42.07M+15.2%|EPS: $-1.19-10.2%MissForm 10-Q - Q3 2024
Period End: Sep 30, 2024|Filed: Nov 6, 2024|Revenue: $11.61M+8.2%|EPS: $-0.27+17.4%BeatForm 10-Q - Q2 2024
Period End: Jun 30, 2024|Filed: Aug 7, 2024|Revenue: $19.88M+36.1%|EPS: $-0.24+4.3%BeatForm 10-Q - Q1 2024
Period End: Mar 31, 2024|Filed: May 8, 2024|Revenue: $6.47M+12.2%|EPS: $-0.35+20.7%MissForm 10-K - FY 2023
Period End: Dec 31, 2023|Filed: Mar 18, 2024|Revenue: $36.53M+46.9%|EPS: $-1.08+12.2%Miss